212 related articles for article (PubMed ID: 32948541)
21. Leukocyte adhesion to P-selectin and the inhibitory role of Crizanlizumab in sickle cell disease: A standardized microfluidic assessment.
Man Y; Goreke U; Kucukal E; Hill A; An R; Liu S; Bode A; Solis-Fuentes A; Nayak LV; Little JA; Gurkan UA
Blood Cells Mol Dis; 2020 Jul; 83():102424. PubMed ID: 32208292
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics, pharmacodynamics, safety, and efficacy of crizanlizumab in patients with sickle cell disease.
Kanter J; Brown RC; Norris C; Nair SM; Kutlar A; Manwani D; Shah N; Tanaka C; Bodla S; Sanchez-Olle G; Albers U; Liles D
Blood Adv; 2023 Mar; 7(6):943-952. PubMed ID: 36355805
[TBL] [Abstract][Full Text] [Related]
23. Short- and long-term follow-up and additional benefits in a sickle cell disease patient experienced severe crizanlizumab infusion-related vaso-occlusive crisis: A case report.
Alshurafa A; Yassin MA
Front Med (Lausanne); 2022; 9():1048571. PubMed ID: 36523780
[TBL] [Abstract][Full Text] [Related]
24. Profile of crizanlizumab and its potential in the prevention of pain crises in sickle cell disease: evidence to date.
Riley TR; Riley TT
J Blood Med; 2019; 10():307-311. PubMed ID: 31507334
[TBL] [Abstract][Full Text] [Related]
25. Emerging Therapies for the Management of Pain and Vaso-Occlusive Crises in Patients With Sickle Cell Disease: A Systematic Review of Randomized Controlled Trials.
Lowe M; Bambhroliya Z; Patel H; Patel VJ; Vudugula SA; Cheruvu NP; Raza S; Okunlola OI
Cureus; 2023 Apr; 15(4):e38014. PubMed ID: 37223201
[TBL] [Abstract][Full Text] [Related]
26. Advancements in Sickle Cell Disease (SCD) Treatment: A Review of Novel Pharmacotherapies and Their Impact on Patient Outcomes.
Khan SJ; Zaidi SAT; Murtaza SF; Asif M; Kumar V
Cureus; 2023 Aug; 15(8):e42847. PubMed ID: 37664319
[TBL] [Abstract][Full Text] [Related]
27. A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma.
Franken MG; Leeneman B; Gheorghe M; Uyl-de Groot CA; Haanen JBAG; van Baal PHM
Eur J Cancer; 2019 Dec; 123():58-71. PubMed ID: 31670077
[TBL] [Abstract][Full Text] [Related]
28. Magnesium for treating sickle cell disease.
Than NN; Soe HHK; Palaniappan SK; Abas AB; De Franceschi L
Cochrane Database Syst Rev; 2019 Sep; 9(9):CD011358. PubMed ID: 31498421
[TBL] [Abstract][Full Text] [Related]
29. Use of Disease-Modifying Treatments in Patients With Sickle Cell Disease.
Newman TV; Yang J; Suh K; Jonassaint CR; Kane-Gill SL; Novelli EM
JAMA Netw Open; 2023 Nov; 6(11):e2344546. PubMed ID: 37991760
[TBL] [Abstract][Full Text] [Related]
30. Comparative pharmacovigilance assessment of adverse events associated with the use of hydroxyurea, L-glutamine, voxelotor, and crizanlizumab in sickle cell disease.
Chen M; Hankins JS; Zhang M; Ataga KI
Am J Hematol; 2024 Feb; 99(2):E37-E41. PubMed ID: 37950855
[TBL] [Abstract][Full Text] [Related]
31. Magnesium for treating sickle cell disease.
Than NN; Soe HHK; Palaniappan SK; Abas AB; De Franceschi L
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD011358. PubMed ID: 28409830
[TBL] [Abstract][Full Text] [Related]
32. Systematic literature review and Bayesian network meta-analysis of episodic cluster headache drugs.
Pompilio G; Migliore A; Integlia D
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1631-1640. PubMed ID: 33629333
[TBL] [Abstract][Full Text] [Related]
33. Design of the DOVE (Determining Effects of Platelet Inhibition on Vaso-Occlusive Events) trial: A global Phase 3 double-blind, randomized, placebo-controlled, multicenter study of the efficacy and safety of prasugrel in pediatric patients with sickle cell anemia utilizing a dose titration strategy.
Hoppe CC; Styles L; Heath LE; Zhou C; Jakubowski JA; Winters KJ; Brown PB; Rees DC; Heeney MM
Pediatr Blood Cancer; 2016 Feb; 63(2):299-305. PubMed ID: 26402148
[TBL] [Abstract][Full Text] [Related]
34. A critical evaluation of crizanlizumab for the treatment of sickle cell disease.
Karki NR; Saunders K; Kutlar A
Expert Rev Hematol; 2022 Jan; 15(1):5-13. PubMed ID: 34942078
[TBL] [Abstract][Full Text] [Related]
35. Crizanlizumab in sickle cell disease.
Kaur K; Kennedy K; Liles D
Pain Manag; 2023 Oct; ():. PubMed ID: 37850353
[TBL] [Abstract][Full Text] [Related]
36. An update review of new therapies in sickle cell disease: the prospects for drug combinations.
Lugthart S; Ginete C; Kuona P; Brito M; Inusa BPD
Expert Opin Pharmacother; 2024 Feb; 25(2):157-170. PubMed ID: 38344818
[TBL] [Abstract][Full Text] [Related]
37. Red blood cell transfusion to treat or prevent complications in sickle cell disease: an overview of Cochrane reviews.
Fortin PM; Hopewell S; Estcourt LJ
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012082. PubMed ID: 30067867
[TBL] [Abstract][Full Text] [Related]
38. Comparative Efficacy of Treatments for Previously Treated Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis.
Maiese EM; Ainsworth C; Le Moine JG; Ahdesmäki O; Bell J; Hawe E
Clin Ther; 2018 Mar; 40(3):480-494.e23. PubMed ID: 29500140
[TBL] [Abstract][Full Text] [Related]
39. Pharmacotherapeutical strategies in the prevention of acute, vaso-occlusive pain in sickle cell disease: a systematic review.
Sins JWR; Mager DJ; Davis SCAT; Biemond BJ; Fijnvandraat K
Blood Adv; 2017 Aug; 1(19):1598-1616. PubMed ID: 29296801
[TBL] [Abstract][Full Text] [Related]
40. Long-term biological effects in sickle cell disease: insights from a post-crizanlizumab study.
Liles DK; Shah NR; Scullin B; Gordeuk VR; Smith WR; Kanter J; Achebe MM; Boccia R; Crary SE; Kraft WK; Archer N; Cataldo V; Hardesty BM; Idowu M; Desai PC; Ikeda A; Puthenveetil G; Hassell KL; Sarnaik S; Kutlar A
Br J Haematol; 2021 Nov; 195(4):e150-e153. PubMed ID: 34611900
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
